Cargando…

Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma

PURPOSE: Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulanthaivelu, Roshini, Kohan, Andres, Hinzpeter, Ricarda, Liu, Zhihui Amy, Hope, Andrew, Huang, Shao Hui, Waldron, John, O’Sullivan, Brian, Ortega, Claudia, Metser, Ur, Veit-Haibach, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638017/
https://www.ncbi.nlm.nih.gov/pubmed/36353565
http://dx.doi.org/10.3389/fonc.2022.952763
_version_ 1784825313185759232
author Kulanthaivelu, Roshini
Kohan, Andres
Hinzpeter, Ricarda
Liu, Zhihui Amy
Hope, Andrew
Huang, Shao Hui
Waldron, John
O’Sullivan, Brian
Ortega, Claudia
Metser, Ur
Veit-Haibach, Patrick
author_facet Kulanthaivelu, Roshini
Kohan, Andres
Hinzpeter, Ricarda
Liu, Zhihui Amy
Hope, Andrew
Huang, Shao Hui
Waldron, John
O’Sullivan, Brian
Ortega, Claudia
Metser, Ur
Veit-Haibach, Patrick
author_sort Kulanthaivelu, Roshini
collection PubMed
description PURPOSE: Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical and radiomic parameters derived from both PET/CT and MR. METHODS: Retrospective evaluation of 124 NPC patients with PET/CT and radiotherapy planning MR (RP-MR). Primary tumors were segmented using dedicated software (LIFEx version 6.1) from PET, CT, contrast-enhanced T1-weighted (T1-w), and T2-weighted (T2-w) MR sequences with 376 radiomic features extracted. Summary statistics describe patient, disease, and treatment characteristics. The Kaplan–Meier (KM) method estimates overall survival (OS) and progression-free survival (PFS). Clinical factors selected based on univariable analysis and the multivariable Cox model were subsequently constructed with radiomic features added. RESULTS: The final models comparing clinical, clinical + RP-MR, clinical + PET/CT and clinical + RP-MR + PET/CT for OS and PFS demonstrated that combined radiomic signatures were significantly associated with improved survival prognostication (AUC 0.62 vs 0.81 vs 0.75 vs 0.86 at 21 months for PFS and 0.56 vs 0.85 vs 0.79 vs 0.96 at 24 months for OS). Clinical + RP-MR features initially outperform clinical + PET/CT for both OS and PFS (<18 months), and later in the clinical course for PFS (>42 months). CONCLUSION: Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with baseline clinical and MR-based radiomic features.
format Online
Article
Text
id pubmed-9638017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96380172022-11-08 Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma Kulanthaivelu, Roshini Kohan, Andres Hinzpeter, Ricarda Liu, Zhihui Amy Hope, Andrew Huang, Shao Hui Waldron, John O’Sullivan, Brian Ortega, Claudia Metser, Ur Veit-Haibach, Patrick Front Oncol Oncology PURPOSE: Radiomics is an emerging imaging assessment technique that has shown promise in predicting survival among nasopharyngeal carcinoma (NPC) patients. Studies so far have focused on PET or MR-based radiomics independently. The aim of our study was to evaluate the prognostic value of clinical and radiomic parameters derived from both PET/CT and MR. METHODS: Retrospective evaluation of 124 NPC patients with PET/CT and radiotherapy planning MR (RP-MR). Primary tumors were segmented using dedicated software (LIFEx version 6.1) from PET, CT, contrast-enhanced T1-weighted (T1-w), and T2-weighted (T2-w) MR sequences with 376 radiomic features extracted. Summary statistics describe patient, disease, and treatment characteristics. The Kaplan–Meier (KM) method estimates overall survival (OS) and progression-free survival (PFS). Clinical factors selected based on univariable analysis and the multivariable Cox model were subsequently constructed with radiomic features added. RESULTS: The final models comparing clinical, clinical + RP-MR, clinical + PET/CT and clinical + RP-MR + PET/CT for OS and PFS demonstrated that combined radiomic signatures were significantly associated with improved survival prognostication (AUC 0.62 vs 0.81 vs 0.75 vs 0.86 at 21 months for PFS and 0.56 vs 0.85 vs 0.79 vs 0.96 at 24 months for OS). Clinical + RP-MR features initially outperform clinical + PET/CT for both OS and PFS (<18 months), and later in the clinical course for PFS (>42 months). CONCLUSION: Our study demonstrated that PET/CT-based radiomic features may improve survival prognostication among NPC patients when combined with baseline clinical and MR-based radiomic features. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638017/ /pubmed/36353565 http://dx.doi.org/10.3389/fonc.2022.952763 Text en Copyright © 2022 Kulanthaivelu, Kohan, Hinzpeter, Liu, Hope, Huang, Waldron, O’Sullivan, Ortega, Metser and Veit-Haibach https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kulanthaivelu, Roshini
Kohan, Andres
Hinzpeter, Ricarda
Liu, Zhihui Amy
Hope, Andrew
Huang, Shao Hui
Waldron, John
O’Sullivan, Brian
Ortega, Claudia
Metser, Ur
Veit-Haibach, Patrick
Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
title Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
title_full Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
title_fullStr Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
title_full_unstemmed Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
title_short Prognostic value of PET/CT and MR-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
title_sort prognostic value of pet/ct and mr-based baseline radiomics among patients with non-metastatic nasopharyngeal carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638017/
https://www.ncbi.nlm.nih.gov/pubmed/36353565
http://dx.doi.org/10.3389/fonc.2022.952763
work_keys_str_mv AT kulanthaiveluroshini prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT kohanandres prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT hinzpeterricarda prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT liuzhihuiamy prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT hopeandrew prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT huangshaohui prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT waldronjohn prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT osullivanbrian prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT ortegaclaudia prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT metserur prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma
AT veithaibachpatrick prognosticvalueofpetctandmrbasedbaselineradiomicsamongpatientswithnonmetastaticnasopharyngealcarcinoma